NCT02888301

18F-Clofarabine PET/CT in Imaging Cancer Patients Before and After Interventions

The Biodistribution of [18F]-Clofarabine in Cancer Patients Before and After Interventions That Increase the Activity of Deoxycytidine Kinase

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 12 (actual)
• Sponsor: Jonsson Comprehensive Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This clinical trial studies 18F-clofarabine positron emission tomography (PET)/computed tomography (CT) in imaging patients with cancer before and after treatment with a therapy that activates the patient's immune system (immunotherapy). PET/CT scans give detailed pictures of areas inside the body. 18F-clofarabine is a drug that contains a radioactive substance that is taken up by cells expressing deoxycytidine kinase (dCK), which is highly expressed in activated immune cells, making them light up during PET/CT scans. Doctors also want to know how 18F-clofarabine is distributed throughout the body before and after treatment with immunotherapies.

Detailed description

PRIMARY OBJECTIVES: I. To determine whether positron emission tomography (PET) using the new imaging agent 18F-clofarabine can be used for imaging cancer, and whether interventions that activate the immune system can change the biodistribution of 18F-clofarabine. OUTLINE: Patients receive 18F-clofarabine intravenously (IV) and undergo PET/CT scan at baseline and 2-4 weeks after completion of immunotherapy.

Conditions

• Malignant Neoplasm

Interventions

Type	Name	Description
PROCEDURE	Computed Tomography	Undergo 18F-clofarabine PET/CT
RADIATION	Fluorine F 18 Clofarabine	Given IV
PROCEDURE	Positron Emission Tomography	Undergo 18F-clofarabine PET/CT

Timeline

• Start date: 2015-06-12
• Primary completion: 2018-04-30
• Completion: 2018-04-30
• First posted: 2016-09-05
• Last updated: 2020-08-12

Locations

1 site across 1 country: United States